Torrent Pharma Inc.

Company overview. Torrent Pharma Inc. (TPI) is the wholly owned U.S. subsidiary of Torrent Pharmaceuticals Ltd., d/b/a Torrent Pharma, an Indian multinational generic-drug manufacturer headquartered in Ahmedabad, Gujarat. TPI was established in 2004 to commercialize the parent's products in the United States and is headquartered at 150 Allen Road, Basking Ridge, New Jersey; it is incorporated in Delaware. The parent, founded in 1959 by U. N. Mehta as Trinity Laboratories and later renamed, is part of the Torrent Group and is publicly listed in India (NSE: TORNTPHARM; BSE: 500420). It reports roughly 17,000–20,000 employees and FY2025 revenue of about ₹11,516 crore (≈US$1.3 billion) per its annual report; TPI itself is a small U.S. commercial and regulatory operation.

Products / operations. TPI is an operating company, not an NPE. It is the U.S. marketing and distribution arm for Torrent's generic formulations, holding Abbreviated New Drug Applications (ANDAs) filed with the FDA; the parent's FY2025 report cites 124 cumulative ANDA approvals. U.S. offerings span cardiovascular, CNS, gastrointestinal, diabetes and other therapeutic areas — including generics of losartan, valsartan, olmesartan, clopidogrel, armodafinil-class CNS drugs and the first generic dichlorphenamide (Keveyis). Manufacturing is largely in India (e.g., Mehsana, Dahej, Vizag), augmented by the 2018 acquisition of U.S.-based Bio-Pharm, Inc. through TPI. The parent also sells branded generics in India and other emerging markets.

Patent-litigation posture. The tracked data show one U.S. case, with TPI as a defendant and zero as plaintiff — the classic profile of an operating company defending Hatch-Waxman infringement suits rather than asserting patents. The sole tracked matter sits in the District of Delaware, a routine venue for ANDA litigation, not an NPE-favored forum such as the Eastern District of Texas.

Notable case/context. The tracked case is Merck Sharp & Dohme Corp. v. Torrent Pharmaceuticals Ltd. et al. (D. Del., filed 2019-02-13), an ANDA/§271(e)(2) action concerning U.S. Patent 7,326,708 (sitagliptin phosphate, Januvia/Janumet) that was consolidated into the In re Sitagliptin Phosphate ('708 & '921) Patent Litigation. It ended in a February 2020 consent judgment and dismissal with prejudice under a settlement agreement. The entity's pattern is conventional generic-drug patent defense.